Current and future advances in practice: SAPHO syndrome and chronic non-bacterial osteitis (CNO).

IF 2.1 Q3 RHEUMATOLOGY Rheumatology Advances in Practice Pub Date : 2024-10-14 eCollection Date: 2024-01-01 DOI:10.1093/rap/rkae114
Victoria Furer, Mitsumasa Kishimoto, Tetsuya Tomita, Ori Elkayam, Philip S Helliwell
{"title":"Current and future advances in practice: SAPHO syndrome and chronic non-bacterial osteitis (CNO).","authors":"Victoria Furer, Mitsumasa Kishimoto, Tetsuya Tomita, Ori Elkayam, Philip S Helliwell","doi":"10.1093/rap/rkae114","DOIUrl":null,"url":null,"abstract":"<p><p>Synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome is a rare, underdiagnosed disease with a wide clinical spectrum. Sterile bone inflammation, predominantly of the anterior chest, and skin manifestations (palmoplantar pustulosis, psoriasis vulgaris and acne) are the key features of SAPHO, which shares certain similarities with SpA. SAPHO is closely related to paediatric chronic non-bacterial osteitis (CNO), a spectrum of autoinflammatory bone diseases. The aetiology of SAPHO is considered multifactorial based on a complex interplay of genetic, immune and infectious factors. Despite the increasing awareness of SAPHO/CNO, diagnostic delay is common, as validated classification and diagnostic criteria are lacking. Treatment of SAPHO represents a challenge and includes anti-inflammatory drugs, antibiotics, bisphosphonates, synthetic conventional DMARDs and off-label use of anti-cytokine biologics and Janus kinase inhibitors. This review summarizes the current diagnostic and practical treatment approach to SAPHO/CNO and highlights the ongoing research endeavours concerning the definition and validation of diagnostic criteria, core domains and treatment.</p>","PeriodicalId":21350,"journal":{"name":"Rheumatology Advances in Practice","volume":"8 4","pages":"rkae114"},"PeriodicalIF":2.1000,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11474108/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rheumatology Advances in Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/rap/rkae114","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome is a rare, underdiagnosed disease with a wide clinical spectrum. Sterile bone inflammation, predominantly of the anterior chest, and skin manifestations (palmoplantar pustulosis, psoriasis vulgaris and acne) are the key features of SAPHO, which shares certain similarities with SpA. SAPHO is closely related to paediatric chronic non-bacterial osteitis (CNO), a spectrum of autoinflammatory bone diseases. The aetiology of SAPHO is considered multifactorial based on a complex interplay of genetic, immune and infectious factors. Despite the increasing awareness of SAPHO/CNO, diagnostic delay is common, as validated classification and diagnostic criteria are lacking. Treatment of SAPHO represents a challenge and includes anti-inflammatory drugs, antibiotics, bisphosphonates, synthetic conventional DMARDs and off-label use of anti-cytokine biologics and Janus kinase inhibitors. This review summarizes the current diagnostic and practical treatment approach to SAPHO/CNO and highlights the ongoing research endeavours concerning the definition and validation of diagnostic criteria, core domains and treatment.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
当前和未来的实践进展:SAPHO 综合征和慢性非细菌性骨炎 (CNO)。
滑膜炎、痤疮、脓疱病、骨质增生和骨炎(SAPHO)综合征是一种罕见的、诊断不足的疾病,临床表现广泛。无菌性骨炎(主要发生在前胸)和皮肤表现(掌跖脓疱病、寻常型银屑病和痤疮)是 SAPHO 的主要特征,与 SpA 有某些相似之处。SAPHO 与小儿慢性非细菌性骨炎(CNO)密切相关,后者是一种自身炎症性骨病。SAPHO 的病因被认为是遗传、免疫和感染等复杂因素相互作用的多因素结果。尽管人们对 SAPHO/CNO 的认识不断提高,但由于缺乏有效的分类和诊断标准,延误诊断的情况十分普遍。SAPHO 的治疗是一项挑战,包括抗炎药物、抗生素、双磷酸盐、合成的传统 DMARDs 以及标签外使用的抗细胞因子生物制剂和 Janus 激酶抑制剂。本综述总结了 SAPHO/CNO 目前的诊断和实际治疗方法,并重点介绍了正在进行的有关诊断标准、核心领域和治疗方法的定义和验证方面的研究工作。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Rheumatology Advances in Practice
Rheumatology Advances in Practice Medicine-Rheumatology
CiteScore
3.60
自引率
3.20%
发文量
197
审稿时长
11 weeks
期刊最新文献
Pain management in people with inflammatory arthritis: British Society for Rheumatology guideline scope. Scleroderma renal crisis, an increasingly rare but persistently challenging condition: a retrospective cohort study. Current and future advances in practice: SAPHO syndrome and chronic non-bacterial osteitis (CNO). Use of over-the-counter supplements, sleep aids and analgesic medicines in rheumatology: results of a cross-sectional survey. The relationship between Zoster serology, vaccination uptake and infection rates: a single-centre cross-sectional study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1